Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Harkess

Orthopaedic Surgery Bradenton, FL Medical Doctor

NPI 1316237183 CMS profile 2783991

8000 Sr 64 E, Bradenton, FL 34212

Open in the dashboard

General payments

$4,692

106 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Harkess of Bradenton, FL is reported in the CMS Open Payments database as having received $4,692 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $662 19
2024 General $527 10
2023 General $505 10
2022 General $861 13
2021 General $631 17
2020 General $498 14
2019 General $1,008 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Harkess
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to John Harkess were reported at $662. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year John Harkess Orthopaedic Surgery median Middle half National median
2019 $1,008 $644 $140–$2,844 $163
2020 $498 $312 $75–$1,860 $114
2021 $631 $520 $117–$2,495 $132
2022 $861 $598 $128–$2,731 $149
2023 $505 $461 $128–$2,264 $160
2024 $527 $497 $134–$2,475 $164
2025 $662 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $2,441 59 payments
  2. DePuy Synthes Sales Inc. $637 5 payments
  3. Smith+Nephew, Inc. $242 3 payments
  4. Allergan Inc. $236 10 payments
  5. Heron Therapeutics, Inc. $193 2 payments
  6. Biocomposites Inc $189 4 payments
  7. Medical Device Business Services, Inc. $175 6 payments
  8. MicroPort Orthopedics Inc $154 3 payments
  9. Zimmer Biomet Holdings, Inc. $133 2 payments
  10. Arthrex, Inc. $81 1 payment
  11. Other $211 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,386 103 payments
  2. Travel and Lodging $214 1 payment
  3. Education $92 2 payments
Products named General payments · program years 2019–2025
  1. ACCOLADE Hips $1,018 20 payments
  2. INSIGNIA $547 16 payments
  3. MAKO $289 7 payments
  4. ACCOLADE Hips $245 6 payments
  5. ATTUNE $229 4 payments
  6. Navio Surgical System $227 2 payments
  7. CORAIL $214 1 payment
  8. AVYCAZ $213 9 payments
  9. ZYNRELEF $193 2 payments
  10. Stimulan $189 4 payments
  11. Other $1,325 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

625

Median for Orthopedic Surgery: 203

Drug cost

$3,358

Median for Orthopedic Surgery: $1,433

Branded share of claims

3.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 162 $1,069
Mupirocin Generic 104 $664
Celecoxib Generic 32 $603
Tramadol Hcl Generic 87 $339
Meloxicam Generic 120 $259
Oxycodone Hcl Generic 33 $165
Ondansetron Odt Ondansetron Brand 20 $100
Ibuprofen Generic 13 $93
Amoxicillin Generic 54 $66

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$260,189

Of which drugs: $24,674

Medicare patients

724

Average age 76

Services billed

5,329

444 women, 280 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 34%
Chronic kidney disease 28%
Diabetes 25%
Depression 25%
Atrial fibrillation 18%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 57 227 $21,339
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 348 2,246 $1,624

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record